8 Recruiting Recurrent Diffuse Large B-Cell Lymphoma Phase 2 Clinical Trials
Active phase 2 studies for recurrent diffuse large b-cell lymphoma enrolling across the USA. Verify eligibility and contact site coordinators.
All Recurrent Diffuse Large B-Cell Lymphoma studiesPhase 2 Studies for Recurrent Diffuse Large B-Cell Lymphoma
🔵 Active, Not Recruiting Phase2
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
📍 University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
View Study & Checklist ➔ 🟢 Recruiting Phase2
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔ 🟢 Recruiting Phase2
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔ 🟢 Recruiting Phase2
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
View Study & Checklist ➔ 🟢 Recruiting Phase2
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔ 🟢 Recruiting Phase2
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
View Study & Checklist ➔